It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Senescence is a state of stable proliferative arrest, generally accompanied by the senescence-associated secretory phenotype, which modulates tissue homeostasis. Enhancer-promoter interactions, facilitated by chromatin loops, play a key role in gene regulation but their relevance in senescence remains elusive. Here, we use Hi-C to show that oncogenic RAS-induced senescence in human diploid fibroblasts is accompanied by extensive enhancer-promoter rewiring, which is closely connected with dynamic cohesin binding to the genome. We find de novo cohesin peaks often at the 3′ end of a subset of active genes. RAS-induced de novo cohesin peaks are transcription-dependent and enriched for senescence-associated genes, exemplified by IL1B, where de novo cohesin binding is involved in new loop formation. Similar IL1B induction with de novo cohesin appearance and new loop formation are observed in terminally differentiated macrophages, but not TNFα-treated cells. These results suggest that RAS-induced senescence represents a cell fate determination-like process characterised by a unique gene expression profile and 3D genome folding signature, mediated in part through cohesin redistribution on chromatin.
Senescence is a state of stable proliferative arrest. Here, the authors perform Hi-C analysis on oncogenic RAS-induced senescence in human fibroblasts and characterize the changes in the 3D genome folding associated with the senescence-specific gene expression profile, which are mediated in part through cohesin redistribution on chromatin.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details










1 Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK (GRID:grid.470869.4) (ISNI:0000 0004 0634 2060)
2 Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK (GRID:grid.470869.4) (ISNI:0000 0004 0634 2060); Epigenetics Programme, The Babraham Institute, Babraham Research Campus, Cambridge, UK (GRID:grid.418195.0) (ISNI:0000 0001 0694 2777)
3 Epigenetics Programme, The Babraham Institute, Babraham Research Campus, Cambridge, UK (GRID:grid.418195.0) (ISNI:0000 0001 0694 2777); Nuclear Dynamics Programme, The Babraham Institute, Babraham Research Campus, Cambridge, UK (GRID:grid.418195.0) (ISNI:0000 0001 0694 2777)
4 MRC Cancer Unit, Hutchison/MRC Research Centre, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934)
5 Laboratory of Genome Structure and Function, Institute of Molecular and Cellular Biosciences, The University of Tokyo, Tokyo, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X)
6 Cell Biology Centre, Institute of Innovative Research, Tokyo Institute of Technology, Yokohama, Japan (GRID:grid.32197.3e) (ISNI:0000 0001 2179 2105)
7 Nuclear Dynamics Programme, The Babraham Institute, Babraham Research Campus, Cambridge, UK (GRID:grid.418195.0) (ISNI:0000 0001 0694 2777); Department of Biological Science, Florida State University, Tallahassee, USA (GRID:grid.255986.5) (ISNI:0000 0004 0472 0419)
8 Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK (GRID:grid.470869.4) (ISNI:0000 0004 0634 2060); Tokyo Tech World Research Hub Initiative (WRHI), Institute of Innovative Research, Tokyo Institute of Technology, Yokohama, Japan (GRID:grid.32197.3e) (ISNI:0000 0001 2179 2105)